With $62 million in series B cash, Pionyr Immunotherapeutics Inc. hopes to "get initial human readouts in a couple of programs – at least one, maybe a second," CEO Steven James told BioWorld. The San Francisco-based company is advancing its Myeloid Tuning technology, which rebalances the tumor microenvironment, an effort that could work especially well with checkpoint inhibitors.